http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
박성호,박한준,윤승환,조준,문창택,장상근,Park, Sung-Ho,Park, Han-Jun,Youn, Seung-Hwan,Cho, Joon,Moon, Chang-Taek,Chang, Sang-Jeun 대한신경외과학회 2001 Journal of Korean neurosurgical society Vol.30 No.1
Object : The rapid and early oxygen delivery to brain tissue was a common therapeutic method in the treatment of severe head injury patients. The purpose of this study was to investigate the effect of increased fraction of inspired oxygen in early stage of severe head injury. Methods : The parameters of research were CSF(cerebral spinal fluid) oxygen pressure($PcsfO_2$), lactate, pH, temperature, and CSF carbon dioxide pressure($PcsfCO_2$). We selected 28 patients with head trauma whose the Glasgow Coma Scale(GCS) score was less than 8 point at admission. All patients were mechanically ventilated and monitored with the commercial ICP monitoring device. Each of parameters was compared as increased fraction of inspired oxygen. In experimental cohort of 14 patients, the mean $PcsfO_2$ level was increased to $314.93{\pm}259.15mmHg$ by raising the $FiO_2$ from 40% to 100% for nine hours(p<0.05). And the mean CSF lactate level was decreased to $2.96{\pm}1.98mmol/L$ on 100% $FiO_2$ as compared with $5.98{\pm}3.25mmol/L$ on 40% $FiO_2$ in control group(p<0.05). The only above two parameters were showed statistically meaningful outcome. Conclusions : Although this study was performed in small cohort and short period, these results supports that increased inspired oxygen therapy in severe head injuried patients was recommended as a modality of treatment in future through the continuous survey.
전자부품 고장모드를 고려한 Built-In-Test 성능분석
서준호(Joon-Ho Seo),고진영(Jin-Young Ko),박한준(Han-Joon Park) 한국항공우주학회 2015 韓國航空宇宙學會誌 Vol.43 No.5
Built-In-Test(이하: BIT)는 항공기 비행안전을 위해 반드시 필요한 기능으로 항공전자 장비의 경우 95% 이상의 높은 고장 진단능력을 요구하고 있다. BIT가 요구도에 명시된 고장진단능력을 만족시키는지 확인하기 위해 BIT 성능분석이 필요하다. BIT 성능분석을 위해 FMECA (Failure Mode Effect Critical Analysis)에 기술된 고장모드를 활용하는 방법이 많이 사용되고 있으나, 본 논문에서는 분석 오류를 최소화할 수 있는 전자부품 기반의 BIT 성능분석 방법론을 소개한다. 또한, BIT 성능분석에서 제외될 수 있는 비행안전에 영향을 미치지 않는 전자부품 및 전자부품의 고장모드를 실제 개발사례에 적용하여 불필요한 BIT기능 구현을 방지하고 정확한 BIT 성능분석을 수행할 수 있도록 하였다. BIT Demo를 수행하여 BIT 성능분석 결과와 실제 BIT 성능이 일치함을 확인하였다. Built-In-Test(hereafter: BIT) is necessary functionality for aircraft flight safety and it requires a high failure detection capacity of more than 95 % in the case of avionics equipment. The BIT coverage analysis is needed to make sure that BIT meets its fault diagnosis capability. FMECA is used a lot of for the BIT coverage analysis. However, in this paper, the BIT coverage analysis based on electronic components is introduced to minimize the analytical error. Further, by applying the failure mode of the electronic components and excluding electronic components that do not affect flight safety, the BIT coverage analysis can be more accurate. Finally, BIT demo was performed and it was confirmed that the performance of the actual BIT matches the analysis of BIT performance.
수술이 불가능한 전이성 또는 국소 진행성 위암 환자에서 선행화학요법의 효과
정유승,박도중,이혁준,김세형,한준구,김태유,방영주,허대석,김노경,김우호,양한광,이건욱,최국진,Chung Yoo-Seung,Park Do Joong,Lee Hyuk-Joon,Kim Se Hyung,Han Joon Koo,Kim Tae-You,Bang Yung-Jue,Heo Dae Seog,Kim No Kyung,Kim Woo Ho,Yang Han-Kwang 대한위암학회 2004 대한위암학회지 Vol.4 No.1
Purpose: The purpose of this study was to evaluate the treatment result of surgical resection after preoperative chemotherapy in inoperable gastric cancer patients. Materials and Methods: We analyzed 18 gastric cancer patients who underwent gastric resection after preoperative chemotherapy because they showed some clinical response to chemotherapy (15 with distant metastasis and 3 with locally advanced lesions). The mean postoperative follow-up period was $15.3\pm15.5$ ($1\∼56$) months. Results: In 15 patients with distant metastasis, 2 ($13.3\%$) showed complete response (CR), 10 ($66.7\%$) partial response (PR), 2 ($13.3\%$) stable disease (SD), and 1 ($6.7\%$) progressive disease (PD). The clinical response rate was $80.0\%$ Five subtotal gastrectomies, 4 total gastrectomies, and 6 extended total gastrectomies were performed. Two cases of CR were alive without recurrence for 4 and 26 months, respectively. Mean survival period in PR case was 37.7 months, but 2 cases of SD and 1 case of PD died after 11.7, 17.9, and 0.9 months, respectively. Postoperative survival was significantly associated with the response to chemotherapy (P<0.01). The mean survival period of the 10 patients with a complete resection was 44.1 months, which was significantly better than that of the 5 patients with an incomplete resection (9.8 months, P=0.03). Among 3 patients with locally advanced gastric cancer, 2 cases showed PR to chemotherapy, and complete resection was possible only by gastrectomy for those patients. Conclusion: In some selected cases, surgical resection was achievable after preoperative chemotherapy for patients with inoperable metastatic or locally advanced gastric cancer.
김부성(Boo Sung Kim),박석영(Suk Young Park),임계순(Kae Soon Im),김영우(Young Woo Kim),백남종(Nam Jong Baeg),한준열(Joon Yeol Han),김석영(Suk Young Kim),박준철(Jun Chul Park) 대한소화기학회 1987 대한소화기학회지 Vol.19 No.2
A palliative treatment technique for esophageal carcinoma using endoscopic Nd - YAG laser therapy is described in 10 patients for whom no curative therapy is possible. Tumors ranged in length frorn 5 to 9 cm with a mean 7.2 cm and luminal diameter ranged from 1 to 5 mm with a mean of 2 mm. The mean number of treatments required to remove obstruction was 5.9 (range 3-12) and the time required to archieve successful luminal opening ranged from 6 to 28 days (mean 13.1 days). The mean total energy required was 33601 Joules. In 10 of 11 cases of treatment, clinical, endoscopic, radiographic improvement was noted. One relapse of dyspnea was successfully managed by the same procedure. Tracheoesophageal fistula occurred in 1 of 11 cases of endoscopic laser therapy. The overall results show that the endoscopic laser therapy relieve dysphagia, the most frequent symptom, rapidly and effectively. Endoscopic laser therapy will be an important palliative treatment of esophageal carcinoma.